- Home
- LSTR vs LEGN Comparison
LSTR vs LEGN Comparison
Compare LSTR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTR | LEGN |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LSTR | LEGN |
|---|---|---|
| Price | $212.69 | $23.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $173.83 | $61.33 |
| AVG Volume (30 Days) | 404.5K | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $4,743,760,000.00 | N/A |
| Revenue This Year | $6.89 | $42.68 |
| Revenue Next Year | $9.05 | $30.52 |
| P/E Ratio | $182.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $119.40 | $16.24 |
| 52 Week High | $228.46 | $45.30 |
Technical Indicators
Market Signals| Indicator | LSTR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 35.74 |
| Support Level | $202.41 | $22.40 |
| Resistance Level | $214.80 | $23.68 |
| Average True Range (ATR) | 5.44 | 1.32 |
| MACD | 0.14 | -0.53 |
| Stochastic Oscillator | 83.76 | 19.34 |
Price Performance
Historical ComparisonAbout LSTR Landstar System Inc.
Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage. Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.